Primary central nervous system lymphoma (PCNSL) is a rare variant of non-Hodgkin's lymphoma, confined to the central nervous system, and accounting for 2% of primary brain tumours. 1 Immunosuppression, including HIV infection, is a substantial risk factor for the condition.
1
Immunosuppression, including HIV infection, is a substantial risk factor for the condition. 2 In HIV-positive patients, there is a strong association with Epstein-Barr virus (EBV) infection. 3 Antimetabolites including methotrexate (MTX) and cytarabine (Ara-C) constitute the backbone of treatment for PCNSL, with or without whole brain radiotherapy (WBRT). A recent randomised phase 2 trial based on this combination demonstrated a 3-year failure-free survival rate of 38%. 4 Auto-SCT with intensive conditioning is also effective in selected patients. A recent large retrospective study demonstrated a 5-year PFS rate of 69% 5 with this approach. HIV-positive patients have been excluded from key studies on the management of PCNSL. Historically, palliation was the objective in this setting, with mean survival of 2 months. 6 Antiretroviral therapy (ART) has been associated with a reduction in the incidence of PCNSL, but outcomes are still inferior to those in HIV-negative patients. [7] [8] [9] Some authors have advised caution in investigating the role of intensive chemotherapy with auto-SCT in HIV-positive patients with PCNSL. 10 This is despite the fact that in the case of systemic (non-CNS) lymphoma in HIV-positive patients, SCT is considered according to the same criteria adopted for HIVnegative patients, based on evidence of two large, retrospective, multi-centre studies. [11] [12] [13] To date, there is a single case report describing the use of high-dose chemotherapy and auto-SCT in a HIV-positive patient with PCNSL.
14 In this letter, we describe our experience in the management of five further HIV-positive patients.
Patient 1: A 50-year-old man presented to the Royal Free London NHS Trust, UK (Royal Free) in October 2011 with drowsiness and confusion. Medical history was notable only for chronic hepatitis B virus (HBV) infection, well controlled on tenofovir. Brain magnetic resonance imaging (MRI) showed a caudate lesion causing hydrocephalus. A new diagnosis of HIV was made with a viral load (VL) of 6025 copies/mL and CD4 count of 21 × 10 6 /L (see Table 1 ). Brain biopsy and staging confirmed PCNSL (diffuse large B-cell subtype (DLBCL)). Biopsy tissue was positive for EBV small RNA (EBER) and cerebrospinal fluid (CSF) PCR was also EBV positive (419 701 copies/mL). ART and chemotherapy were initiated (high-dose MTX (3.5 g/m 2 ) for two cycles, and a further two cycles of high-dose MTX (3.5 g/m 2 , D1) with Ara-C (2 g/m 2 BD, D2/3)). Rituximab was discontinued after one cycle due to transient HBV reactivation.
After chemotherapy, which was well-tolerated, the brain lesion had substantially decreased in size on MRI, and HIV VL was undetectable with a CD4+ cell count of 136 × 10 6 /L. Four weeks later, the patient underwent auto-SCT conditioned with carmustine (400 mg/m 2 , D− 6) and thiotepa (2 × 5 mg/kg, D − 5/ − 4). Recovery was complicated by mild cytopenias associated with treatment for CMV reactivation. CR was achieved and has been maintained 30 months later. HIV and HBV VLs are undetectable and CD4+ cell count is 488 × 10 6 /L. Neuropsychological assessment has revealed some impairment of memory and executive function but the patient lives independently and has resumed work.
Patient 2: A 36-year-old man with a history of chronic hepatitis C virus (HCV) infection (genotype 1A) with cirrhosis, prior HBV infection and past i.v. drug use, presented to the Royal Free in December 2012 with fever, maculopapular rash, headache and confusion. A new diagnosis of HIV was made with a VL of 578 144 copies/mL and a CD4+ cell count of 165 × 10 6 /L. HCV VL was 14 million copies/mL. MRI showed lesions in the corpus callosum and cerebellum, and biopsy and staging confirmed PCNSL (DLBCL). Biopsy tissue was EBER positive and CSF PCR was also positive for EBV (660 659 copies/mL). ART and chemotherapy were initiated (MTX/ARA-C, protocol as above). Chemotherapy was complicated by episodes of Staphylococcus aureus bacteraemia.
After chemotherapy, MRI showed PR with HIV VL of 4614 copies/mL and a CD4 count of 350 × 10 6 /L. The patient was keen for further treatment but declined WBRT on the basis of potential associated neurotoxicity. Eight weeks later he underwent auto-SCT conditioned with carmustine and thiotepa (protocol as above). On day +3 post transplant, the patient developed Klebsiella pneumonia neutropenic sepsis and subsequently, multi-organ failure. Despite maximal support, he died 2 weeks later.
Patient 3: A 46-year-old man presented to the Freiburg Medical Centre (Germany) in November 2010, with an acute history of fever and respiratory symptoms, and a 1-year history of diarrhoea, weight loss and intermittent headache. A new diagnosis of HIV was made with a VL of 5.7 × 10 6 copies/mL and a CD4+ cell count of 44 × 10 6 /L. Bronchoalveolar lavage showed Pneumocystis jiroveci infection and MRI, a frontal lobe lesion. EBER-positive PCNSL (DLBCL) was confirmed. Treatment was commenced with ART and trimethoprim/sulfamethoxazole (cotrimoxazole). After initial rituximab monotherapy, a four-cycle regimen was completed comprising MTX/ARA-C (protocol as above) but with addition of rituximab (375 mg/m 2 , D0) and thiotepa (30 mg/m 2 , D4). A CD4+ cell count of 4250 × 10 6 /L was achieved and maintained throughout the chemotherapy.
The patient proceeded to a carmustine/thiotepa-conditioned auto-SCT (protocol as above), which was well-tolerated. Three years after transplant, he is clinically well and remains in CR.
Patient 4: A 49-year-old man presented acutely with diplopia and cerebellar symptoms in May 2013. He was transferred to the Klinikum Stuttgart (Germany). Medical history included Crohn's disease, not currently requiring treatment. MRI showed basal ganglion and temporal lobe lesions. A new diagnosis of HIV was made with a VL of 847 000 copies/mL and a CD4+ cell count of 100 × 10 6 /L. PCNSL (DLBCL) was confirmed. Serum toxoplasma serology was IgG positive. ART and chemotherapy were initiated, the first two cycles comprising MTX/ARA-C (protocol as above) with rituximab (375 mg/m 2 , D0), followed by a further two cycles with the latter three agents plus thiotepa (30 mg/m 2 , D4). Prophylaxis included cotrimoxazole. Treatment was welltolerated other than episodes of neutropenic fever.
Post-chemotherapy MRI showed a slight increase in perilesional oedema but no clear evidence of disease on positron emission tomography. Four weeks thereafter, the patient underwent carmustine/thiotepa-conditioned auto-SCT (protocol as above) complicated only by a further episode of neutropenic fever. The patient was discharged to a rehabilitation unit. The CD4+ cell count had improved to 570 × 10 6 /L and VL was undetectable, thus cotrimoxazole was stopped. Two weeks later, the patient represented with fever and neurological deterioration. MRI showed increased lesions. Steroids and antibiotics were started and biopsy was repeated. The patient died two weeks after readmission. Biopsy subsequently showed Toxoplasma gondii. High-dose chemotherapy with auto-SCT consolidation has been described as an effective strategy for PCNSL in immunocompetent patients. It is not a treatment that has historically been made available to HIV-positive patients. This report describes our experience of auto-SCT consolidation in the management of five HIV-positive patients with PCNSL. Two of the five patients remain in remission over 2 years post transplant. A third patient is well 7 months post transplant. The strategy is not without risk however, two patients dying from infectious complications. The potential role of auto-SCT in managing HIV-positive patients with PCNSL merits further evaluation through clinical trials. Abbreviations: Ara-C = cytarabine; ART = antiretroviral therapy; Car = carmustine; EFV = efavirenz; FTC = emtricitabin; Kal = Kaletra; MTX = high-dose MTX; R = rituximab; RAL = raltegravir; TDF = tenofovir; Thio = thiotepa; Truv = Truvada; VL = viral load. a Rituximab in the first cycle only.
